ASTRAZENECA PLC-SPONS ADR (AZN) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:AZN • US0463531089

193.03 USD
+5.87 (+3.14%)
At close: Feb 6, 2026
193 USD
-0.03 (-0.02%)
After Hours: 2/6/2026, 8:18:50 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall AZN gets a fundamental rating of 6 out of 10. We evaluated AZN against 191 industry peers in the Pharmaceuticals industry. While AZN has a great profitability rating, there are some minor concerns on its financial health. AZN has a decent growth rate and is not valued too expensively. AZN also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • AZN had positive earnings in the past year.
  • AZN had a positive operating cash flow in the past year.
  • Each year in the past 5 years AZN has been profitable.
  • Each year in the past 5 years AZN had a positive operating cash flow.
AZN Yearly Net Income VS EBIT VS OCF VS FCFAZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 8.21%, AZN belongs to the top of the industry, outperforming 89.53% of the companies in the same industry.
  • AZN's Return On Equity of 20.48% is amongst the best of the industry. AZN outperforms 90.58% of its industry peers.
  • AZN has a Return On Invested Capital of 14.42%. This is amongst the best in the industry. AZN outperforms 94.24% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for AZN is in line with the industry average of 12.65%.
  • The last Return On Invested Capital (14.42%) for AZN is above the 3 year average (11.62%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.21%
ROE 20.48%
ROIC 14.42%
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
AZN Yearly ROA, ROE, ROICAZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

  • AZN has a Profit Margin of 16.17%. This is amongst the best in the industry. AZN outperforms 88.48% of its industry peers.
  • In the last couple of years the Profit Margin of AZN has grown nicely.
  • AZN has a better Operating Margin (24.34%) than 91.10% of its industry peers.
  • In the last couple of years the Operating Margin of AZN has grown nicely.
  • AZN's Gross Margin of 81.90% is amongst the best of the industry. AZN outperforms 85.86% of its industry peers.
  • In the last couple of years the Gross Margin of AZN has remained more or less at the same level.
Industry RankSector Rank
OM 24.34%
PM (TTM) 16.17%
GM 81.9%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
AZN Yearly Profit, Operating, Gross MarginsAZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AZN is still creating some value.
  • AZN has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for AZN has been increased compared to 5 years ago.
  • Compared to 1 year ago, AZN has a worse debt to assets ratio.
AZN Yearly Shares OutstandingAZN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B
AZN Yearly Total Debt VS Total AssetsAZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • AZN has an Altman-Z score of 6.24. This indicates that AZN is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.24, AZN is in the better half of the industry, outperforming 78.01% of the companies in the same industry.
  • The Debt to FCF ratio of AZN is 3.41, which is a good value as it means it would take AZN, 3.41 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.41, AZN belongs to the top of the industry, outperforming 87.96% of the companies in the same industry.
  • A Debt/Equity ratio of 0.61 indicates that AZN is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.61, AZN is not doing good in the industry: 67.02% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 3.41
Altman-Z 6.24
ROIC/WACC1.58
WACC9.15%
AZN Yearly LT Debt VS Equity VS FCFAZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

  • AZN has a Current Ratio of 0.88. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.88, AZN is doing worse than 87.43% of the companies in the same industry.
  • AZN has a Quick Ratio of 0.88. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • AZN's Quick ratio of 0.69 is on the low side compared to the rest of the industry. AZN is outperformed by 86.39% of its industry peers.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.69
AZN Yearly Current Assets VS Current LiabilitesAZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.61% over the past year.
  • The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
  • AZN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.52%.
  • Measured over the past years, AZN shows a quite strong growth in Revenue. The Revenue has been growing by 17.27% on average per year.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%

3.2 Future

  • Based on estimates for the next years, AZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.37% on average per year.
  • Based on estimates for the next years, AZN will show a small growth in Revenue. The Revenue will grow by 7.20% on average per year.
EPS Next Y14.52%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
EPS Next 5Y12.37%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AZN Yearly Revenue VS EstimatesAZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
AZN Yearly EPS VS EstimatesAZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 41.96, AZN can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of AZN indicates a somewhat cheap valuation: AZN is cheaper than 77.49% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of AZN to the average of the S&P500 Index (27.93), we can say AZN is valued expensively.
  • The Price/Forward Earnings ratio is 36.30, which means the current valuation is very expensive for AZN.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AZN indicates a somewhat cheap valuation: AZN is cheaper than 70.68% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of AZN to the average of the S&P500 Index (27.77), we can say AZN is valued slightly more expensively.
Industry RankSector Rank
PE 41.96
Fwd PE 36.3
AZN Price Earnings VS Forward Price EarningsAZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AZN is valued a bit cheaper than the industry average as 79.58% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, AZN is valued a bit cheaper than 77.49% of the companies in the same industry.
Industry RankSector Rank
P/FCF 62.56
EV/EBITDA 30
AZN Per share dataAZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • AZN has an outstanding profitability rating, which may justify a higher PE ratio.
  • AZN's earnings are expected to grow with 12.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.89
PEG (5Y)2.26
EPS Next 2Y13.43%
EPS Next 3Y12.85%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.75%, AZN has a reasonable but not impressive dividend return.
  • AZN's Dividend Yield is rather good when compared to the industry average which is at 0.94. AZN pays more dividend than 92.15% of the companies in the same industry.
  • AZN's Dividend Yield is comparable with the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 1.75%

5.2 History

  • The dividend of AZN has a limited annual growth rate of 1.40%.
  • AZN has been paying a dividend for at least 10 years, so it has a reliable track record.
  • AZN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
AZN Yearly Dividends per shareAZN Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

  • AZN pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
AZN Yearly Income VS Free CF VS DividendAZN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B
AZN Dividend Payout.AZN Dividend Payout, showing the Payout Ratio.AZN Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTRAZENECA PLC-SPONS ADR

NYSE:AZN (2/6/2026, 8:18:50 PM)

After market: 193 -0.03 (-0.02%)

193.03

+5.87 (+3.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-10
Inst Owners49.17%
Inst Owner Change0.59%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap598.50B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target202.76 (5.04%)
Short Float %0.41%
Short Ratio1.8
Dividend
Industry RankSector Rank
Dividend Yield 1.75%
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years1
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)108.28%
PT rev (3m)121.45%
EPS NQ rev (1m)-0.07%
EPS NQ rev (3m)-0.46%
EPS NY rev (1m)2.29%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.57%
Valuation
Industry RankSector Rank
PE 41.96
Fwd PE 36.3
P/S 10.3
P/FCF 62.56
P/OCF 39.53
P/B 13.04
P/tB N/A
EV/EBITDA 30
EPS(TTM)4.6
EY2.38%
EPS(NY)5.32
Fwd EY2.76%
FCF(TTM)3.09
FCFY1.6%
OCF(TTM)4.88
OCFY2.53%
SpS18.75
BVpS14.8
TBVpS-4.36
PEG (NY)2.89
PEG (5Y)2.26
Graham Number39.14
Profitability
Industry RankSector Rank
ROA 8.21%
ROE 20.48%
ROCE 17.6%
ROIC 14.42%
ROICexc 16.02%
ROICexgc 81.56%
OM 24.34%
PM (TTM) 16.17%
GM 81.9%
FCFM 16.46%
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 3.41
Debt/EBITDA 1.34
Cap/Depr 84.97%
Cap/Sales 9.59%
Interest Coverage 10.83
Cash Conversion 73.11%
Profit Quality 101.79%
Current Ratio 0.88
Quick Ratio 0.69
Altman-Z 6.24
F-Score7
WACC9.15%
ROIC/WACC1.58
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y14.52%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
EPS Next 5Y12.37%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.82%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%

ASTRAZENECA PLC-SPONS ADR / AZN FAQ

Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?

ChartMill assigns a fundamental rating of 6 / 10 to AZN.


What is the valuation status for AZN stock?

ChartMill assigns a valuation rating of 4 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.


How profitable is ASTRAZENECA PLC-SPONS ADR (AZN) stock?

ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.


Can you provide the PE and PB ratios for AZN stock?

The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 41.96 and the Price/Book (PB) ratio is 13.04.


What is the expected EPS growth for ASTRAZENECA PLC-SPONS ADR (AZN) stock?

The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 14.52% in the next year.